Highlights

  • Memphasys Limited (ASX:MEM) reported September-quarter invoiced revenue of A$211,000, up 41% quarter on quarter.
  • Customer receipts reached A$183,000, while quarter-end cash totalled A$3.458 million.
  • New Felix distribution agreements covered Poland, the Nordic region and three additional markets.
  • The company received A$3.5 million in loan funding pending shareholder consideration of convertible notes.

Australian reproductive biotechnology company Memphasys Limited (ASX:MEM) is expanding international sales activity for its Felix sperm preparation system. Its September 2026 quarterly report, released in October, records higher invoicing, new distribution agreements and further regulatory approvals. Alongside this commercial activity, the company received additional funding and increased spending on manufacturing inventory. The latest report therefore provides a view of both emerging product sales and the costs of establishing repeat use in fertility clinics. At the time of writing on 19 October 2026, Memphasys Limited (ASX:MEM) shares were trading at AUD 0.005, an increase of 25.00% during the day’s trading session.

Company Business

Memphasys develops and commercialises reproductive biotechnology for assisted reproduction. Its principal commercial product, Felix, prepares sperm for use in fertility treatment. The system combines equipment used by clinics with single-use cartridges required for individual procedures, creating a model in which repeat customer orders depend on routine clinical adoption.

The company works with fertility clinics and distribution partners across Australia, Europe, the Middle East and parts of Asia. Its European network includes agreements in Poland, the Nordic countries, the Czech Republic, Slovakia and Kazakhstan. Its activities also extend to Vietnam, Thailand and Türkiye, where registrations during 2026 enabled commercial sales. Memphasys has previously developed its RoXsta oxidative-stress diagnostic platform, but official company reporting identifies Felix commercialisation as its immediate focus.

Recent Development

In the September quarter, Memphasys added European distribution arrangements with TK Biotech in Poland, NOVIVITAE across Denmark, Sweden, Norway, Finland and Iceland, and INVIDO LAB covering the Czech Republic, Slovakia and Kazakhstan. The disclosed minimum agreement values were €212,000 over two years, €526,500 over three agreement years and €416,200 over three years, respectively. These are contracted minimums over specified periods, not revenue booked entirely in the September quarter.

Regulatory registrations supported commercial activity in South-East Asia and Türkiye. Vietnam’s registration triggered an order for 600 cartridges under a two-year A$530,000 arrangement. In Thailand, approval activated the IVF Envimed distribution agreement; the distributor placed another order for 100 cartridges and three paid consoles. An initial Turkish sale comprised 100 cartridges and two consoles drawn from existing distributor inventory, rather than a new Memphasys cartridge order.

Beyond distributor agreements, the company reported repeat orders from Italy, the United Kingdom and the Middle East and North Africa. In early October, a Stockholm fertility clinic associated with Karolinska placed an initial Felix order for evaluation. Ten additional clinics were trialling the system across Germany, Poland, Sweden, Finland and Denmark. Memphasys also validated an extension of Felix cartridge shelf life from 18 to 24 months, potentially easing inventory management across markets.

Financial Performance and Sector Context

Memphasys disclosed A$211,000 in September-quarter invoiced revenue, compared with A$150,000 in June, an increase of approximately 41%. Customer cash receipts totalled A$183,000; the company cautioned that receipts include payments for earlier invoices and are therefore distinct from current-quarter invoicing. These figures indicate growing commercial activity, although they remain modest relative to operating expenditure.

Net cash used in operating activities was A$1.159 million, compared with A$421,000 in the preceding quarter. September expenditure included approximately A$601,000 paid to manufacturing partners for cartridges and consoles, plus A$165,000 in interest payments. Excluding those two items, the company described operating cash outflow of approximately A$393,000. Quarter-end cash and cash equivalents were A$3.458 million, up from A$1.179 million at 30 June, following receipt of A$3.5 million in funding.

The fertility-technology sector operates within medical-device approval requirements and clinic procurement processes. For Memphasys, regulatory access establishes eligibility to sell in particular jurisdictions, but product evaluations, training and repeat cartridge purchasing determine how rapidly that access converts into invoicing.

Risks to Consider

Operating expenditure currently exceeds customer receipts, making the pace of recurring cartridge sales and inventory conversion relevant to cash management. The A$3.5 million received from Peters Investments is an interest-bearing loan pending approvals for proposed convertible notes. Those notes would carry a 12.5% annual interest rate and conversion terms, creating financing and potential dilution considerations; if approval is not obtained, repayment obligations apply. Contracted purchase minimums also depend on contractual implementation and should not be treated as cash already received.

What to Watch Next

Near-term items include European clinic evaluations, repeat orders and implementation of the Monash IVF trial program in Australia. The company is also progressing US Food and Drug Administration pre-submission engagement following regulatory pathway discussions; US clearance has not been granted. Shareholder votes concerning proposed financing and a one-for-ten share consolidation represent additional corporate milestones.

Key Insights

The September quarter combined higher invoicing and customer receipts with new international distribution and clinic-testing activity. Funding increased reported cash, while manufacturing purchases and financing costs lifted operating cash use. Future disclosures on repeat cartridge demand, regulatory engagement and the proposed financing structure will help clarify how the commercial rollout is progressing.